Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: janakiram m. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Sidana S, et al. Among authors: janakiram m. Haematologica. 2024 Mar 1;109(3):777-786. doi: 10.3324/haematol.2023.283940. Haematologica. 2024. PMID: 37731379 Free PMC article.
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana S, Hosoya H, Jensen A, Liu L, Goyal A, Hovanky V, Sahaf B, Bharadwaj S, Latchford T, Arai S, Leahy S, Mei M, Budde LE, Muffly LS, Frank MJ, Dahiya S, Htut M, Miklos D, Janakiram M. Sidana S, et al. Among authors: janakiram m. Blood Cancer J. 2023 Oct 13;13(1):158. doi: 10.1038/s41408-023-00929-0. Blood Cancer J. 2023. PMID: 37833271 Free PMC article. No abstract available.
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK. Hansen DK, et al. Among authors: janakiram m. Front Immunol. 2024 Jun 10;15:1405452. doi: 10.3389/fimmu.2024.1405452. eCollection 2024. Front Immunol. 2024. PMID: 38915401 Free PMC article.
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: janakiram m. Blood. 2024 Oct 4:blood.2024025945. doi: 10.1182/blood.2024025945. Online ahead of print. Blood. 2024. PMID: 39365257
Targeting cancer stem cells in multiple myeloma.
Gunes EG, Gunes M, Yu J, Janakiram M. Gunes EG, et al. Among authors: janakiram m. Trends Cancer. 2024 Aug;10(8):733-748. doi: 10.1016/j.trecan.2024.06.002. Epub 2024 Jul 5. Trends Cancer. 2024. PMID: 38971642 Free article. Review.
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. Bhansali RS, et al. Among authors: janakiram m. Blood Adv. 2024 Jul 9;8(13):3507-3518. doi: 10.1182/bloodadvances.2024012800. Blood Adv. 2024. PMID: 38739715 Free PMC article.
89 results